↓ Skip to main content

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial

Overview of attention for article published in Cardiovascular Diabetology, November 2022
Altmetric Badge

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial
Published in
Cardiovascular Diabetology, November 2022
DOI 10.1186/s12933-022-01666-7
Pubmed ID
Authors

Daniel Guldager Kring Rasmussen, Michael K. Hansen, Joseph Blair, Timothy A. Jatkoe, Bruce Neal, Morten A. Karsdal, Federica Genovese

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 16%
Student > Bachelor 4 13%
Student > Master 2 6%
Other 1 3%
Unspecified 1 3%
Other 2 6%
Unknown 16 52%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 16%
Medicine and Dentistry 3 10%
Mathematics 1 3%
Unspecified 1 3%
Unknown 21 68%